Login to Your Account

Vimizim’s Briefing Docs Signal Smooth FDA Panel for Biomarin

By Randy Osborne
Staff Writer

Friday, November 15, 2013
Likely breathing easier ahead of Tuesday’s FDA advisory committee meeting is Biomarin Pharmaceutical Inc., with Vimizim (elosulfase alfa) slated to undergo scrutiny as an enzyme replacement therapy (ERT) for mucopolysaccharidosis Type IVA, also called Morquio A syndrome.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription